Pirtobrutinib, Lisaftoclax, and Rituximab for relapsed DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diffuse large B-cell lymphoma (DLBCL) and have already tried at least one standard treatment that didn't work or came back.
- Your cancer can be seen on a PET-CT scan and is at least 1.5 cm in size.
- Your liver and kidney function are good enough, as shown by blood tests (e.g., bilirubin, creatinine within certain limits).
- You must be able to swallow pills without difficulty.
- You are not pregnant or breastfeeding, and you agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called pirtobrutinib combined with standard chemotherapy (R-CHOP) for people with a type of large B-cell lymphoma that hasn't been treated before. The goal is to see if adding this drug helps the treatment work better.
This trial tests a new combination of targeted therapy (pirtobrutinib) with standard chemotherapy (Pola-R-CHP) for people newly diagnosed with a type of large B-cell lymphoma that is not the germinal center B-cell subtype. The goal is to see if adding pirtobrutinib helps the treatment work better.
This trial tests whether a combination of two newer drugs can help people with certain types of B-cell lymphoma that have come back or not responded to treatment. The drugs target cancer cells differently than older treatments, possibly offering a new option.
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
This trial tests a new targeted therapy (pirtobrutinib) combined with standard chemo-immunotherapy, with or without an extra targeted drug (polatuzumab vedotin), for people whose large B-cell lymphoma has returned or not responded after prior BTK inhibitor treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.